Clinical course of a cohort with type 2 diabetes mellitus after endocrine assessment. A 26-week study

Herranz-Antolín, Sandra; Frutos, Visitación Álvarez-de; Torralba, Miguel

doi:10.1016/j.endien.2018.04.001

Cited by 1 publication

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum UA concentration is associated with DR, DN, and albuminuria severity in T2DM [30]. In the current study, GBC and/or MF exhibited no significant difference in the serum UA level in patients with T2DM, consistent with other studies [31,32]. Also, no significant difference between parameters when patients were taken GBC alone or with NF.…”

Section: Resultssupporting

confidence: 89%

Subgrouping of Type 2 Diabetes Mellitus Based on Proteinuria and Diabetic Control for Treatment and Follow-Up

et al. 2021

View full text Add to dashboard Cite

Patients with type 2 diabetes mellitus (T2DM) exhibit improved symptoms at the start of treatment, but their conditions subsequently deteriorate after a few months of treatment. In the present study, patients treated with glibenclamide and metformin were followed up to evaluate the efficacy of treatment based on some biochemical parameters in T2DM subgroups. The patients with T2DM were subgrouped according to their glycated hemoglobin (HbA1c), sex, urinary albumin to creatinine ratio (UACR), and uric acid UA levels. A total of 662 patients participated in the study, which aimed to follow up with glycated hemoglobin (HbA1c), fasting blood sugar (FBS), uric acid (UA), UACR, and lipid profiles at the beginning of treatment and after 2 and 4 months. Results showed that the best treatment effect occurred when patients were classified according to the UACR and HbA1c. In general, all parameters, especially lipid profile and UA levels, changed when patients exhibit proteinuria compared with those in normal UACR patients. Depending on the glycemic control subgroups, all parameters were higher in patients with poor glycemic control than those with fair glycemic control, except for HDLc, which was lowest in the poor-control patients. The parameters revealed significant improvement (p<0.05) in lipids, UA, UACR, and HbA1c after 2 months of treatment but subsequently remained slightly increased after 4 months. The parameters measured by using subgroups were better than those obtained from the whole group. The patients who initially experienced improved symptoms tended to ignore regular treatment and restricted diet, thereby worsening the measured parameters.

show abstract

Section: Resultssupporting

confidence: 89%